Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2012
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
ApoE, Alzheimer's and Lipoprotein Biology (Q5)
Organizer(s) Joachim Herz, David M. Holtzman and Eric M. Parker
February 26—March 2, 2012
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Oct 26, 2011
Late Abstract Deadline: Dec 2, 2011
Scholarship Deadline: Oct 26, 2011
Early Registration Deadline: Jan 4, 2012
Sponsored by AstraZeneca Pharmaceuticals, L.P., Biogen Idec and Merck & Co., Inc.
Summary of Meeting:
Apolipoprotein E4 (ApoE4) genotype is the primary risk factor for late-onset Alzheimer’s Disease. Approximately one fifth of the human population are ApoE4 carriers, yet more than 17 years after its discovery, the molecular basis by which this common allele causes neurodegeneration is still not understood. One major reason is the lack of effective communication between lipid researchers who have investigated the role of ApoE as a plasma lipid transport protein, and neuroscientists who are unfamiliar with the complex biochemistry of lipid metabolism and the cell biology of ApoE receptors. This is confounded by the methodological difficulty of studying lipid metabolism and lipoprotein transport in the brain and the paucity of pioneering work tackling this problem. Yet, the solution to one of the most pressing socioeconomic problems of our times, the looming Alzheimer’s Disease epidemic, depends on our ability to dissect and understand the molecular mechanism by which ApoE4 is causing this disease. The purpose of this highly interdisciplinary meeting on ApoE, Alzheimer’s and lipoprotein biology is to bring together a critical mass of experts with complementary expertise from these different fields, but who do not normally collaborate or attend the same conferences. In this manner, we envisage this meeting serving as the main catalyst for communication and collaboration between lipid and lipoprotein researchers, neurogeneticists, cell biologists and synaptic neurophysiologists. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent conference on Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies, which will share opening keynote addresses and a fourth day of sessions with this meeting.
View Scholarships/Awards
Apolipoprotein E4 (ApoE4) genotype is the primary risk factor for late-onset Alzheimer’s Disease. Approximately one fifth of the human population are ApoE4 carriers, yet more than 17 years after its discovery, the molecular basis by which this common allele causes neurodegeneration is still not understood. One major reason is the lack of effective communication between lipid researchers who have investigated the role of ApoE as a plasma lipid transport protein, and neuroscientists who are unfamiliar with the complex biochemistry of lipid metabolism and the cell biology of ApoE receptors. This is confounded by the methodological difficulty of studying lipid metabolism and lipoprotein transport in the brain and the paucity of pioneering work tackling this problem. Yet, the solution to one of the most pressing socioeconomic problems of our times, the looming Alzheimer’s Disease epidemic, depends on our ability to dissect and understand the molecular mechanism by which ApoE4 is causing this disease. The purpose of this highly interdisciplinary meeting on ApoE, Alzheimer’s and lipoprotein biology is to bring together a critical mass of experts with complementary expertise from these different fields, but who do not normally collaborate or attend the same conferences. In this manner, we envisage this meeting serving as the main catalyst for communication and collaboration between lipid and lipoprotein researchers, neurogeneticists, cell biologists and synaptic neurophysiologists. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent conference on Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies, which will share opening keynote addresses and a fourth day of sessions with this meeting.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, FEBRUARY 26
MONDAY, FEBRUARY 27
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
TUESDAY, FEBRUARY 28
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
WEDNESDAY, FEBRUARY 29
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
THURSDAY, MARCH 1
FRIDAY, MARCH 2
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, FEBRUARY 26
19:15—21:30
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online.
*
Eric M. Parker,
Synergy Partners R&D Solutions, USA
Robert W. Mahley,
J. David Gladstone Institutes, USA
Neurobiology of Apolipoprotein E in Alzheimer’s Disease and Traumatic Brain Injury
Neurobiology of Apolipoprotein E in Alzheimer’s Disease and Traumatic Brain Injury
Robert C. Malenka,
Stanford University School of Medicine, USA
Molecular Mechanisms of Synaptic Plasticity
Molecular Mechanisms of Synaptic Plasticity
08:00—11:15
ApoE and ApoE Receptors - Structure, Function and Genetics
Meeting has ended...abstracts no longer viewable online.
*
Robert W. Mahley,
J. David Gladstone Institutes, USA
Yadong Huang,
Gladstone Institute of Neurological Disease and UCSF, USA
ApoE4 Structure–Related Detrimental Effects and Structure Correctors
ApoE4 Structure–Related Detrimental Effects and Structure Correctors
Guojun Bu,
Mayo Clinic, USA
ApoE Receptor LRP1 in Brain Lipid Metabolism, Synaptic Functions and Abeta Clearance
ApoE Receptor LRP1 in Brain Lipid Metabolism, Synaptic Functions and Abeta Clearance
Carlos Cruchaga,
Washington University School of Medicine, USA
What Do Genetic Studies Tell Us about the Role of APP and APOE in Risk for AD?
What Do Genetic Studies Tell Us about the Role of APP and APOE in Risk for AD?
Eric Reiman,
Banner Alzheimer's Institute, USA
Brain Imaging and ApoE4 in the Presymptomatic Study and Treatment of Alzheimer's Disease
Brain Imaging and ApoE4 in the Presymptomatic Study and Treatment of Alzheimer's Disease
Thomas L. Kukar,
Emory University, USA
Short Talk: Lysine 624 of the Amyloid Precursor Protein (APP) is a Critical Determinant of Amyloid-beta Peptide Length
Short Talk: Lysine 624 of the Amyloid Precursor Protein (APP) is a Critical Determinant of Amyloid-beta Peptide Length
Huntington Potter,
University of Colorado Denver, USA
Short Talk: Use of Parabiosis to Investigate the Role of Apolipoprotein E as Amyloid Catalyst and Peripheral Sink in Alzheimer’s Disease
Short Talk: Use of Parabiosis to Investigate the Role of Apolipoprotein E as Amyloid Catalyst and Peripheral Sink in Alzheimer’s Disease
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
08:15—11:30
Definition of the Problem: Epidemiology of Sports and Military TBI
Meeting has ended...abstracts no longer viewable online.
*
Sam Gandy,
Mount Sinai Medical Center, USA
Steven T. DeKosky,
University of Virginia, USA
Traumatic Brain Injury: Multiple Causes, and Short and Long-Term Consequences
Traumatic Brain Injury: Multiple Causes, and Short and Long-Term Consequences
Andrew I. R. Maas,
Antwerp University Hospital - UZA, Belgium
Definition and Epidemiology in TBI
Definition and Epidemiology in TBI
Kevin M. Guskiewicz,
University of North Carolina, USA
Clinical Spectrum of Sports TBI
Clinical Spectrum of Sports TBI
Victoria E. Johnson,
University of Pennsylvania, USA
Short Talk: Persistent Inflammation in the Corpus Callosum for Many Years following a Single TBI in Humans
Short Talk: Persistent Inflammation in the Corpus Callosum for Many Years following a Single TBI in Humans
Jenna M. Ziebell,
University of Arizona, USA
Short Talk: Morphological Alignment of Microglia across Cortical Layers after Experimental Diffuse Brain Injury
Short Talk: Morphological Alignment of Microglia across Cortical Layers after Experimental Diffuse Brain Injury
Ramesh C. Nayak,
MSDx Inc, USA
Short Talk: Recirculating Phagocytes are a Novel Source of Biomarkers for Brain Injury
Short Talk: Recirculating Phagocytes are a Novel Source of Biomarkers for Brain Injury
Sarah C. Hellewell,
National Trauma Research Institute, Monash University, Australia
Short Talk: EPO Ameliorates Axonal Damage, Attenuates Macrophage Infiltration and Restores Motor Function in a Combined Model of TAI and Hypoxia
Short Talk: EPO Ameliorates Axonal Damage, Attenuates Macrophage Infiltration and Restores Motor Function in a Combined Model of TAI and Hypoxia
17:00—19:00
ApoE, APP and Tau - Physiology and Pathophysiology
Meeting has ended...abstracts no longer viewable online.
David M. Holtzman,
Washington University, USA
ApoE and apoE Receptors: Influence on Abeta Metabolism
ApoE and apoE Receptors: Influence on Abeta Metabolism
Irene Knuesel,
Roche Innovation Center Basel, Switzerland
Modulation of Amyloid and Tau Pathology by the ApoE Receptor Ligand, Reelin
Modulation of Amyloid and Tau Pathology by the ApoE Receptor Ligand, Reelin
Ina Caesar,
Mount Sinai Medical Center, USA
Short Talk: Molecular Imaging of ApoE Isoform-Related Protein Conformation Changes in Human Alzheimer Brain
Short Talk: Molecular Imaging of ApoE Isoform-Related Protein Conformation Changes in Human Alzheimer Brain
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
17:00—19:00
Sports-Related TBI and CTE
Meeting has ended...abstracts no longer viewable online.
Thomas M. Talavage,
Purdue University, USA
Neuroimaging of Concussive and Subconcussive Injury: Potential Clinical Application
Neuroimaging of Concussive and Subconcussive Injury: Potential Clinical Application
*
Jeffrey T. Barth,
University of Virginia Health System, USA
Neuropsychological Assessment of Sports Concussion and CTE: From Dings to Dementia
Neuropsychological Assessment of Sports Concussion and CTE: From Dings to Dementia
Ann C. McKee,
Boston University / VA Boston Healthcare System, USA
Molecular Neuropathology of Chronic Traumatic Encephalopathy and Encephalomyelopathy
Molecular Neuropathology of Chronic Traumatic Encephalopathy and Encephalomyelopathy
08:00—11:15
Lipid Transport and Metabolism in the Brain and in the Vasculature
Meeting has ended...abstracts no longer viewable online.
Cheryl Wellington,
University of British Columbia, Canada
From Concussion to Dementia: A Key Role for Apolipoprotein E
From Concussion to Dementia: A Key Role for Apolipoprotein E
Peter Tontonoz,
University of California, Los Angeles, USA
Control of Brain Metabolism and LDLR Family Expression by LXRs
Control of Brain Metabolism and LDLR Family Expression by LXRs
Gary E. Landreth,
Case Western Reserve University, USA
Retinoid X Receptors as Therapeutic Targets in Alzheimer's Disease
Retinoid X Receptors as Therapeutic Targets in Alzheimer's Disease
Anders Nykjaer,
Aarhus University, Denmark
Sortilins in Neuronal Plasticity and Degeneration
Sortilins in Neuronal Plasticity and Degeneration
Stephanie J. Soscia,
Massachusetts General Hospital, USA
Short Talk: Analysis of the ABCA7 Transporter, Brain Lipids, and Alzheimer’s Disease
Short Talk: Analysis of the ABCA7 Transporter, Brain Lipids, and Alzheimer’s Disease
Celina Zerbinatti,
Merck Research Laboratories, USA
Short Talk: Cholesterol Ester Transfer Protein Deficient Polymorphisms Alter CSF Biomarkers and Reduce Alzheimer's Disease-Related Cognitive Impairment in Apolipoprotein E4 Carriers
Short Talk: Cholesterol Ester Transfer Protein Deficient Polymorphisms Alter CSF Biomarkers and Reduce Alzheimer's Disease-Related Cognitive Impairment in Apolipoprotein E4 Carriers
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
08:00—10:40
Classical Approaches to TBI: Metabolic and Axonal Dysfunction
Meeting has ended...abstracts no longer viewable online.
*
Steven T. DeKosky,
University of Virginia, USA
Nick Tustison,
University of Pennsylvania School of Medicine, USA
Understanding the Inside of the Black Box: Optimizing Approaches for the Analysis of Diffusion Tensor Imaging and Cortical Maps in TBI
Understanding the Inside of the Black Box: Optimizing Approaches for the Analysis of Diffusion Tensor Imaging and Cortical Maps in TBI
Stephen T. Ahlers,
Naval Medical Research Center, USA
Considerations of Long-Term Sequalae in an Animal Model of Blast-Induced Mild Traumatic Brain Injury
Considerations of Long-Term Sequalae in an Animal Model of Blast-Induced Mild Traumatic Brain Injury
Sam Gandy,
Mount Sinai Medical Center, USA
Novel Drugs Enhance Cognition and Stimulate Neurogenesis While Reducing Synaptic Generation of Abeta42
Novel Drugs Enhance Cognition and Stimulate Neurogenesis While Reducing Synaptic Generation of Abeta42
Christopher Giza,
University of California, Los Angeles, USA
Metabolism, Neural Activation and Plasticity after TBI: A Developmental Perspective
Metabolism, Neural Activation and Plasticity after TBI: A Developmental Perspective
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
10:40—11:15
Molecular Biomarker Approach to TBI and CTE I
Meeting has ended...abstracts no longer viewable online.
Kaj Blennow,
University of Gothenburg, Sweden
CSF Biomarkers of TBI
CSF Biomarkers of TBI
Theresa Currier Thomas,
University of Kentucky, USA
Short Talk: Diffuse Brain Injury Causes Up-Regulation of Thrombospondins in the Rat Thalamus; Implications for a Role in Post-Traumatic Circuit Reorganization?
Short Talk: Diffuse Brain Injury Causes Up-Regulation of Thrombospondins in the Rat Thalamus; Implications for a Role in Post-Traumatic Circuit Reorganization?
17:00—19:00
Cell Biology and Development
Meeting has ended...abstracts no longer viewable online.
Steven J. Burden,
New York University Medical Center, USA
An Lrp4-Centric View of Neuromuscular Synapse Formation
An Lrp4-Centric View of Neuromuscular Synapse Formation
Weichun Lin,
University of Texas Southwestern Medical Center, USA
Regulation of Synapse Formation and Maturation by ApoE Receptors and Amyloid Precursor Protein
Regulation of Synapse Formation and Maturation by ApoE Receptors and Amyloid Precursor Protein
Graham Collingridge,
Mount Sinai Hospital, Canada
Just Another Kinase Involved in Hippocampal Long-Term Depression: Implications for AD
Just Another Kinase Involved in Hippocampal Long-Term Depression: Implications for AD
Junichi Takagi,
Osaka University, Japan
Short Talk: Structural Basis for Peptide Ligand Recognition by LR11/sorLA Vps10p Domain
Short Talk: Structural Basis for Peptide Ligand Recognition by LR11/sorLA Vps10p Domain
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
17:00—17:35
Molecular Biomarker Approach to TBI and CTE II
Meeting has ended...abstracts no longer viewable online.
*
Ann C. McKee,
Boston University / VA Boston Healthcare System, USA
Kevin K. W. Wang,
University of Florida, McKnight Brain Institute, USA
Biomarkers for Traumatic Brain Injury, Potential Relevance to Chronic Traumatic Encephalopathy Development
Biomarkers for Traumatic Brain Injury, Potential Relevance to Chronic Traumatic Encephalopathy Development
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
17:35—19:00
Animal Models of Blast TBI
Meeting has ended...abstracts no longer viewable online.
Lee E. Goldstein,
Boston University, USA
Injury Mechanisms, Neuropathology, and Sequelae in a Murine Blast Neurotrauma Model
Injury Mechanisms, Neuropathology, and Sequelae in a Murine Blast Neurotrauma Model
Andrew R. Mayer,
Mind Research Network, USA
Short Talk: Biomarkers of Increased Diffusion Anisotropy in Semi-Acute Mild Traumatic Brain Injury: A Longitudinal Perspective in Humans
Short Talk: Biomarkers of Increased Diffusion Anisotropy in Semi-Acute Mild Traumatic Brain Injury: A Longitudinal Perspective in Humans
08:00—11:00
ApoE, ApoE Receptors and Abeta - Synaptic Modulation, Processing and Transport I
Meeting has ended...abstracts no longer viewable online.
*
Eric M. Parker,
Synergy Partners R&D Solutions, USA
Gabriella D'Arcangelo,
Rutgers University, USA
Regulation of Dendritogenesis and Spine Formation by Reelin
Regulation of Dendritogenesis and Spine Formation by Reelin
Joachim Herz,
University of Texas Southwestern Medical Center, USA
A Molecular Basis for the Role of ApoE4 in Alzheimer’s Disease
A Molecular Basis for the Role of ApoE4 in Alzheimer’s Disease
Steve W. Barger,
University of Arkansas for Medical Sciences, USA
Short Talk: ApoE/Reelin Receptors are a Point of Convergence for Three Paths to Alzheimer’s Disease
Short Talk: ApoE/Reelin Receptors are a Point of Convergence for Three Paths to Alzheimer’s Disease
Justin Howard Trotter,
University of South Florida Health, USA
Short Talk: Coordinated Regulation of Dab1 by Fyn and Cdk5
Short Talk: Coordinated Regulation of Dab1 by Fyn and Cdk5
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
08:00—11:00
Insights into CTE from Recent Advances in Molecular Pathology of Neurodegenerative Diseases
Meeting has ended...abstracts no longer viewable online.
Kathryn E. Saatman,
University of Kentucky, USA
The Calpain/Calpastatin System in TBI and Chronic Neurodegeneration
The Calpain/Calpastatin System in TBI and Chronic Neurodegeneration
David L. Brody,
Washington University School of Medicine, USA
Changes in Amyloid Beta Protein Correlate with Neurological Status after TBI
Changes in Amyloid Beta Protein Correlate with Neurological Status after TBI
David K. Menon,
University of Cambridge, UK
Short Talk: PiB PET in TBI: Preliminary Results and Neuropathological Correlates
Short Talk: PiB PET in TBI: Preliminary Results and Neuropathological Correlates
Rachel Bennett,
Massachusetts General Hospital, USA
Short Talk: Human Apolipoprotein E4 Accelerates Tau Pathology following TBI in 3xTg-AD Mice
Short Talk: Human Apolipoprotein E4 Accelerates Tau Pathology following TBI in 3xTg-AD Mice
Andrei Irimia,
University of California, Los Angeles, USA
Short Talk: Patient-Tailored Longitudinal Quantification of Brain Atrophy in Chronic Traumatic Encephalopathy using Multimodal Neuroimaging
Short Talk: Patient-Tailored Longitudinal Quantification of Brain Atrophy in Chronic Traumatic Encephalopathy using Multimodal Neuroimaging
Linda J. Van Eldik,
University of Kentucky, USA
Short Talk: A Novel Class of CNS Drugs Administered Hours Post-Injury Alters Pathology Progression and Improves Neurologic Outcomes in Closed Head Injury Models
Short Talk: A Novel Class of CNS Drugs Administered Hours Post-Injury Alters Pathology Progression and Improves Neurologic Outcomes in Closed Head Injury Models
17:00—19:00
ApoE, ApoE Receptors and Abeta - Synaptic Modulation, Processing and Transport II
Meeting has ended...abstracts no longer viewable online.
John R. Cirrito,
Washington University, School of Medicine, USA
Synaptic-Dependent Regulation of Abeta Metabolism and APP Processing in Vivo
Synaptic-Dependent Regulation of Abeta Metabolism and APP Processing in Vivo
Jorge J. Palop,
University of California, San Francisco, USA
Neuronal Rhythms, Network Hypersynchrony, and Cognitive Dysfunction in Alzheimer’s Disease
Neuronal Rhythms, Network Hypersynchrony, and Cognitive Dysfunction in Alzheimer’s Disease
Thomas E. Willnow,
Max-Delbrueck-Center for Molecular Medicine, Germany
Role of SORLA/SORL1 in APP Sorting and Alzheimer's Disease
Role of SORLA/SORL1 in APP Sorting and Alzheimer's Disease
Claus U. Pietrzik,
University Medical Center of the Johannes Gutenberg-University, Germany
Short Talk: Genetic Evidence for LRP1 and PrPc Mediated Amyloid-beta Transcytosis Across the Blood-Brain Barrier
Short Talk: Genetic Evidence for LRP1 and PrPc Mediated Amyloid-beta Transcytosis Across the Blood-Brain Barrier
Following Session is for Clinical and Molecular Biology of Acute and Chronic Traumatic Encephalopathies (Q6)
17:00—19:00
Experimental Therapeutic Approaches to TBI/CTE Based on Insights from Recent Advances in Molecular Pathology of Neurodegenerative Diseases
Meeting has ended...abstracts no longer viewable online.
*
Stephen T. Ahlers,
Naval Medical Research Center, USA
Milos D. Ikonomovic,
University of Pittsburgh, USA
Statin Therapy in Experimental TBI
Statin Therapy in Experimental TBI
Fernando Gomez-Pinilla,
University of California at Los Angeles, USA
Diet and Exercise Therapy Against Brain Trauma
Diet and Exercise Therapy Against Brain Trauma
Effie Mitsis,
James J. Peters VAMC, USA
Short Talk: Resting State Functional Connectivity in Blast-Related Mild Traumatic Brain Injury in OIF/OEF Combat Veterans with and without PTSD
Short Talk: Resting State Functional Connectivity in Blast-Related Mild Traumatic Brain Injury in OIF/OEF Combat Veterans with and without PTSD
08:00—11:00
Therapeutic and Diagnostic Approaches to Neurodegeneration and Metabolism I (Joint)
Meeting has ended...abstracts no longer viewable online.
*
Kelly Bales,
Pfizer, Inc., USA
Eric M. Parker,
Synergy Partners R&D Solutions, USA
Physiologic and Therapeutic Roles of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)
Physiologic and Therapeutic Roles of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)
Edwin J. Weeber,
University of South Florida, USA
Cognition Enhancement by ApoE Receptor Activators
Cognition Enhancement by ApoE Receptor Activators
Michael P. Vitek,
Duke University Medical Center and Cognosci, Inc., USA
Neuroprotective and Anti-Inflammatory Therapeutics for Traumatic Brain Injury and Alzheimer’s Disease Based Upon Apolipoprotein-E
Neuroprotective and Anti-Inflammatory Therapeutics for Traumatic Brain Injury and Alzheimer’s Disease Based Upon Apolipoprotein-E
Mark A. Mintun,
Avid Radiopharmaceuticals, Inc., USA
Interaction of Aging, ApoE Genotype and Amyloid Deposition as Revealed by Amyloid Imaging
Interaction of Aging, ApoE Genotype and Amyloid Deposition as Revealed by Amyloid Imaging
17:00—19:00
Therapeutic and Diagnostic Approaches to Neurodegeneration and Metabolism II (Joint)
Meeting has ended...abstracts no longer viewable online.
Suzanne Craft,
Wake Forest University School of Medicine, USA
Insulin Resistance and AD Pathology: Interactions with Apolipoprotein E
Insulin Resistance and AD Pathology: Interactions with Apolipoprotein E
Eric R. Siemers,
Eli Lilly and Company, USA
Clinical Efficacy of Novel Amyloid-Lowering Therapies
Clinical Efficacy of Novel Amyloid-Lowering Therapies
Kelly Bales,
Pfizer, Inc., USA
HDAC Inhibition: A Novel Pathway for Modulating Apolipoprotein E Levels
HDAC Inhibition: A Novel Pathway for Modulating Apolipoprotein E Levels
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
